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10 Abstract
11 Routinely collected electronic health records (EHRs) are increasingly used for research. With their use comes the opportunity for
12 large-scale, high-quality studies that can address questions not easily answered by randomised clinical trials or classical cohort
13 studies involving bespoke data collection. However, the use of EHRs generates challenges in terms of ensuring methodological
14 rigour, a potential problem when studying complex chronic diseases such as diabetes. This review describes the promises and
15 potential of EHRs in the context of diabetes research and outline key areas of caution with examples. We consider the difficulties
16 in identifying and classifying diabetes patients, in distinguishing between prevalent and incident cases and in dealing with the
17 complexities of diabetes progression and treatment. We also discuss the dangers of introducing time-related biases and describe
18 the problems of inconsistent data recording, missing data and confounding. Throughout, we provide practical recommendations
19 for good practice in conducting EHR studies and interpreting their results.
20 Keywords Diabetes . Electronic health records . Epidemiology . Observational studies . Primary care . Review . Secondary care
21
22 Abbreviations
24 CKD5 Chronic kidney disease
26 CVD7 Cardiovascular disease
28 EHR9 Electronic health record
30 GP1 General practitioner/General practice2
33 Introduction
34 A greater understanding of the changing patterns of treatment,
35 patient demographics, risk factors and disease burden is vital
36 to inform clinical care and public health policy in diabetes.
37 RCTs are key but will not answer all questions as they have
38 several limitations: (1) they often have insufficient power and
39length of follow-up to examine clinical endpoints; (2) aspects
40of patient behaviour and clinical care are likely to differ in
41trials compared with real-world settings and (3) important
42groups, such as women of childbearing age, individuals with
43multimorbidities and ethnic minorities, may be under-
44represented in clinical trial populations [1–3]. Similarly, clas-
45sical cohort studies involving bespoke data collection are ex-
46pensive and time consuming and rarely have long-term fol-
47low-up for participants beyond the initial study period.
48The use of electronic health records (EHRs) for research
49allows us to overcome many of these limitations and address
50important scientific questions. Post marketing and surveil-
51lance studies using EHRs are key for speeding up access
52to new drugs [4]. Recognising this, the ADA recently en-
53dorsed the use of evidence from high-quality observational
54studies to aid therapeutic decision making [5, 6]. In recent
55years, the use of EHRs for research has grown tremendously
56and the potential for observational studies using EHRs to
57generate valid estimates of causal associations is beginning
58to be explored. Though EHRs have the potential to produce
59high-quality research, major challenges exist. In this narra-
60tive review, we describe the promises and potential of EHRs,
61outline some key areas of caution and provide practical rec-
62ommendations for using EHRs in the context of diabetes
63research.
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64 The promise of EHR data
65 The term ‘electronic health record’ encompasses a wide vari-
66 ety of data sources including, but not limited to, routinely
67 collected primary and secondary care records, disease-
68 specific registries and health insurance claims databases
69 (Table 1). Several key potential advantages of EHRs are
70 outlined in the Text box.
71 EHRs are widely used to enable contemporary estimation
72 of disease incidence or prevalence [13–15], study prospective
73 associations between risk factors and disease outcomes [16],
74 establish trends over time [17] and model the best use of
75 healthcare resources [18, 19]. Importantly, many EHRs also
76 provide high-quality data onmedication prescribing. In claims
77 databases, any medication claimed for under a health insur-
78 ance policy is typically recorded by the insurance provider. In
79 primary care databases, information on medications pre-
80 scribed by the general practitioner (GP), such as number of
81 tablets and dosage, are recorded, while in pharmacy databases,
82 data on dispensing of medications are also available.
83 Traditionally, data from EHRs have been used to assess ad-
84 verse effects of treatment, especially unexpected effects.
85 Improvements in the availability and quality of data and ad-
86 vances in study designs and analytical methods have broad-
87 ened the value of such studies. This enables researchers to
88answer questions of both regulatory and epidemiological im-
89portance more quickly than with traditional study designs
90where data are collected in real time after conception of the
91study. EHRs have already been used to answer a range of
92questions concerning diabetes risk and treatment effects [20,
9321].
94Although no one database is likely to have an entire,
95complete picture of an individual’s medical history, linkage
96between EHRs can improve completeness and validity of
97key morbidity data, as demonstrated for myocardial infarc-
98tion [22], and enable the study of exposures and outcomes
99which would otherwise be impossible in unlinked data. In
100the UK, primary care data are routinely linked to Office for
101National Statistics death certificate data (providing detailed
102information on causes of death), hospital data (providing
103information on diagnoses from secondary care), depriva-
104tion data and disease-specific registries (e.g. for cancer,
105acute coronary syndromes) [12]. Similar linkages are also
106available between databases in the USA [23]. The avail-
107ability of linked data depends greatly on the data provider,
108data infrastructure and, in the USA, healthcare provider. In
109Denmark and other Scandinavian countries, however, in-
110formation across a wide range of databases (such as hospi-
111tal records [11], prescriptions [24] and disease registries
112[25]) are all linked by a unique identity code assigned to
113each resident either at birth or when they become a resident
114[6], resulting in virtually complete population coverage
115and linkage. Linkages to biobanks can also provide highly
116detailed information on laboratory results and genetic
117markers (see for example http://www.bbmri-eric.eu/
118(accessed 5 Jun 2017); [26, 27]. Further, although
119different EHRs may use differing classifications and
120coding systems (e.g. Read codes vs ICD), combining data
121from multiple sources is still possible since mappings
122between coding and classification systems are generally
123available, or may be done on a study by study basis.
124Possible pitfalls of EHRs
125We summarise a broad range of issues relevant to the study of
126diabetes using EHRs. A previous systematic review has de-
127tailed the methodological challenges of studying glucose-
128lowering medications in observational studies [28].
129Therefore, issues specific to the study of drug effects, such
130as confounding by indication (whereby the reason for being
131prescribed [or not prescribed] the drug is itself related to the
132risk of the outcome), are not covered here.
133Accurate identification of diabetes status
134Accurate disease ascertainment and categorisation is an essen-
135tial first step towards identifying patterns of disease, and
• Studies are cost effective to conduct as data are 
already collected for other purposes
• Data are not affected by recall bias as they are 
collected prospectively in real time
• Data are available in near-real time, vital for a 
fast-changing field such as diabetes
• Large sample sizes allow for increased power to 
conduct granular comparisons between population 
subgroups and to investigate rare outcomes [7, 8]
• High validity of coded data for many diagnoses 
[9–11]
• Detailed prescribing and dispensing information 
often available for medications 
• Potential for linkage across a range of healthcare 
settings
• Samples often representative of the source 
population, allowing for accurate generalisations [6, 
12]
Advantages of research using EHRs
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136 targeting interventions and resources appropriately.
137 Challenges for diabetes researchers include the long latency
138 between disease onset and diagnosis, and misclassification of
139 diabetes type (e.g. older-onset type 1 diabetes being
140 misclassified as type 2). Such misclassification may result in
141 a biased estimation of the impact of diabetes on outcomes.
142 Medication records may be used to supplement clinical data
143 in identifying individuals with diabetes but this can present
144 additional problems (e.g. metformin is used for the treatment
145 of polycystic ovary syndrome and insulin is used in both type
146 1 and type 2 diabetes). Algorithms combining both diagnostic
147 and supporting information (e.g. medication, laboratory re-
148 sults, age, BMI) have been developed to overcome these chal-
149 lenges [14, 29].
150 Differentiating between prevalent vs incident disease
151 and treatment
152 In many EHRs, individuals often join the database at time
153 points with no clear clinical significance. For example, in pri-
154 mary care records, the first database entry is made on the date of
155 an individual’s initial registration with the GP. At the initial
156 visit, a GP may enter details for all pre-existing conditions.
157 Therefore, in the period immediately after an individual enters
158the database, it may be unclear whether a new diabetes diag-
159nostic code reflects existing diabetes or a new diagnosis [30].
160This may limit the ability to adjust for diabetes duration, which
161may be an important source of confounding, particularly in
162studies comparing diabetes treatments. It is also typically un-
163clear whether a new medication record in this early period
164reflects continuation of an existing therapy or incident use.
165Including prevalent users in a study of drug effects can lead
166to serious bias if treatment effects or risks vary over time, as is
167often (although not always) the case in diabetes. This is because
168prevalent users will have already ‘survived’ the early period of
169therapy [31]. For this reason, so-called new-user designs are
170generally encouraged, wherein new drug users are typically
171identified by requiring a certain period (e.g. 12 months) of
172follow-up before the first prescription [32]. However, it should
173be acknowledged that such designs may come at the price of
174loss in power, since we often reduce the sample to individuals
175with shorter exposure or duration of disease, which may reduce
176the number of long-term outcomes observed.
177Use of future information
178When an EHR study is designed, it is often the case that all, or a
179large proportion, of the follow-up information is already
t1:1 Table 1 Examples of EHRs
EHR Data types available Examples
Primary care databases Diagnoses of chronic and acute conditions, prescription data,
information on processes of care procedures and monitoring
(e.g. blood tests, BP, screening and annual health checks),
as well as demographic and lifestyle information such as
age, sex, smoking and alcohol consumption
Clinical Practice Research Datalink (UK)
QRESEARCH (UK)
SAIL database (Wales)
Primary Care Sentinel Surveillance Network (Canada)
Integrated Primary Care Information Database (Netherlands)
The Information System for the Development of Research
in Primary Care (Spain)
Secondary care
databases
Admissions to inpatient, outpatient and emergency services,
diagnostic and procedural codes and administrative
information such as length of stay, ward and specialty area
Hospital Episode Statistics (UK)
National Registry of Patients (Denmark)
Disease registries Detailed information on the relevant condition (e.g. cancer
registries have details of date of diagnosis, cancer type,
grade and treatments received but may lack information
on comorbidities and concomitant medication)
Primary Care Cardiovascular Database (Sweden)
Global Rare Diseases Patient Registry Data Repository
(USA)
Myocardial Ischaemia National Audit Project (UK)
Danish Huntington Register (Denmark)
Insurance claims
databases
Demographic information on the individual enrolled in the
insurance plan, as well as details of medical history that
have been covered and medication that has been claimed
for under the insurance plan (e.g. information on
prescription drugs and hospital inpatient and outpatient care)
Medicare (US)
Health Maintenance Organizations (HMOs) such as
Molina Healthcare, Kaiser Permanente, United
Healthcare (USA)
National Health Insurance Research Database (Taiwan)
PHARM (Italy)























180 available. Using future information when defining cohort in-
181 clusion, exposure status or covariate values at the time of study
182 entry risks biasing the results because patient outcomes have
183 influenced how they are dealt with in the study prior to their
184 outcome [33]. As a simple example, consider a study of BMI
185 and future risk of cardiovascular risk using a diabetes registry.
186 Each individual may have multiple measures of BMI from the
187 time they enter the registry until the time they exit the database
188 or develop cardiovascular disease (CVD). If all BMI measures
189 are used to determine whether an individual is overweight at
190 study entry (e.g. by calculating an average BMI over follow-
191 up), then the target comparison of ‘overweight’ vs ‘normal
192 weight’ becomes a comparison of ‘average overweight’ vs ‘av-
193 erage normal weight’, leading to unclear interpretation and po-
194 tential selection bias. An average normal weight could mask
195 weight loss as a consequence of undiagnosed CVD, or a CVD
196 diagnosis that appears late in the course of disease. Another
197 problem of using future information is that concerning ‘immor-
198 tal time bias’. This term is associated with the concept that
199 during certain time periods during follow-up, a specific out-
200 come cannot occur. Levesque et al [34] demonstrated this using
201 data from a Canadian health database: they defined statin users
202 as those with 12 or more months of continuous use during
203 follow-up, and compared rates of insulin initiation (a proxy
204 for diabetes progression) from study entry between users and
205 non-users. This led to an estimated protective effect of statins.
206 The problemwith this approach is that anyone experiencing the
207 outcome (insulin initiation) before completing 12 months of
208 statin use would be classified as a non-user as their time at risk
209 in the study would end at this point so they could not fulfil the
210 definition of being a statin user. The corollary to this is that
211 those categorised as statin users could not by definition have
212 experienced the outcome (insulin initiation) prior to starting a
213 statin and completing 12 months of statin use, creating a period
214 of ‘immortal time’ for statin users. When this event-free per-
215 son-time is included in the denominator, outcome rates in the
216 exposed group are biased downwards, leading to an overall
217 bias towards a protective effect of exposure. When the authors
218 instead used a correct time-updated approach wherein an indi-
219 vidual’s exposure status was updated from non-user to user
220 once that individual reached 1 year from their first statin pre-
221 scription, the protective effect of statins disappeared. Another
222 solution might have been to start follow-up 1 year after the first
223 statin prescription for statin users and to use a matched date for
224 non-statin-users. Immortal time bias, along with other time-
225 related biases, has been previously described in reference to
226 studies of metformin and cancer risk in patients with diabetes
227 [35] and in the previously referenced review by Patorno et al
228 [28].When defining inclusion criteria and exposures/covariates
229 intended to reflect the point of study entry, it is worth asking the
230 question ‘Have I only used information that I would have had at
231 the time of recruitment had I conducted this study in real time?’
232 If the answer is no, then bias may inadvertently be introduced.
233Dealing with the complexities of diabetes progression
234One of the most common scenarios in which bias from use of
235future information manifests in diabetes epidemiology is
236when dealing with treatment switches over the course of fol-
237low-up. Studies may restrict the study population to individ-
238uals who remain on a single therapy regime throughout fol-
239low-up, leading to selection bias or immortal time. One solu-
240tion is to model the treatment of interest as time-varying, thus
241allowing the inclusion of all patients by accounting for their
242treatment modality. Such a solution would be relevant to the
243study of any exposure (e.g. BMI, HbA1c, eGFR) that changes
244as the disease progresses. Although an important advantage of
245EHRs is the ability to collect longitudinal data to investigate
246such time-varying exposures, dealing with confounding in-
247variably becomes more complex in this situation. When con-
248sidering how to model changes in exposure status through
249time, one must determine first whether information on time-
250varying confounders (confounders of the association between
251exposure and outcome that also change through time) is avail-
252able in the database and second whether the time-varying
253confounders may also be affected by prior exposure status.
254If time-varying confounding is thought to be present, then
255adjustment for the value of the confounder at study entry only
256may not remove confounding for those whose exposure status
257changes over the course of follow-up. This can be overcome
258by using methods such as time-varying Cox proportional haz-
259ards models, which time-update the value of the confounder as
260it changes. However, if prior exposure is expected to affect
261future values of the confounder, then this method may not be
262appropriate as the adjustment may remove the effect of treat-
263ment that acts via future values of the confounder. These lim-
264itations of standard analysis methods in the presence of time-
265dependent confounders affected by prior exposures for diabe-
266tes research have been described in more detail in a systematic
267review [36], and more generally elsewhere [37]. Such issues
268occur both when examining time-varying treatment and time-
269varying risk factors such as BMI or glucose control or pro-
270gressive conditions such as chronic kidney disease (CKD).
271For example, if we wish to examine the effect of CKD stage
272on mortality in individuals with diabetes, then HbA1c may be
273a time-varying confounder of the association but CKD stage
274may also influence future HbA1c. Methodological approaches
275to dealing with time-varying confounders affected by prior
276treatment include inverse probability weighting of marginal
277structural models, g-computation and g-estimation [38]. In
278theory, these methods correctly adjust for the time-varying
279confounding without losing any effect of exposure that acts
280via future values of the confounder, subject to certain assump-
281tions [38]. If such methodologies are not feasible, simpler
282study designs in which exposures are assumed to remain fixed
283from study entry (analogous to intention to treat analyses) may
284still be used to examine exposure/outcome associations but
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285 such designs can only answer more limited questions that
286 ignore the reality of individuals changing treatments over
287 time.
288 Finally, another consideration when dealing with time-
289 varying exposure, is the extent to which changes in exposure
290 are a result of reverse causality. For instance, many people
291 lose weight shortly before diagnosis of diabetes, due to under-
292 lying ill health. Using weight measures shortly before diagno-
293 sis may lead to the erroneous conclusion that low weight is a
294 risk factor for diabetes. It is advisable to conduct a sensitivity
295 analysis to determine whether this may be an issue (e.g. by
296 defining the date of exposure as being 6–12 months after the
297 date observed within the EHR) [30].
298 Context in which data are collected
299 Understanding the purpose for which the data were initially
300 collected andmethods of data collection are critical to accurate
301 analysis and interpretation of EHR research and for assessing
302 the likelihood of encountering problems of missing data and
303 unmeasured confounding.
304 Selection biases arising from data availability Primary and
305 secondary care data are collected as and when individuals visit
306 their GP or hospital and therefore samples from these data-
307 bases may over-represent less-healthy individuals. This may
308 present less of a problem in studies restricted to individuals
309 with diabetes, since they will likely visit the GP on a semi-
310 regular basis and thus have similar amounts and types of data
311 recorded. However, if a general population comparison group
312 is selected, those with available data may not be representative
313 of the broader population. Even among individuals who do
314 visit their GP regularly, there may be less data collected on
315 those who are perceived to be healthier or at lower risk, as GPs
316 are less likely to perform routine investigations in this group.
317 Different considerations apply for claims databases: these may
318 have an over-representation of healthier individuals, as those
319 with pre-existing conditionsmay find it harder to receive med-
320 ical cover.
321 Missing data EHR data, for the reasons outlined above,
322 likely suffer from missing data issues. Often, we classify
323 variables based on the presence or absence of codes. For
324 example, when determining whether an individual has had
325 a previous CVD event, the presence of a code will indi-
326 cate ‘yes’, while the absence of a code will likely indicate
327 ‘no’, and thus we can derive a CVD status for 100% of
328 individuals (albeit with the possibility of misclassifica-
329 tion). However, for measures such as blood pressure or
330 HbA1c, missing data are likely to indicate that the value
331 has not been recorded. Analysing only the subset of indi-
332 viduals that have complete data on all necessary covari-
333 ates is a commonly used approach but whether or not this
334is reasonable depends on how the missingness is associ-
335ated the outcome of interest [39]. Advanced methods such
336as multiple imputation may be used to assess the extent to
337which missing data may affect the analysis and to obtain
338more valid estimates of association if data are missing at
339random, meaning that the reason for missingness is inde-
340pendent of the value after conditioning on other measured
341covariates [40]. Unfortunately, this is an untestable as-
342sumption [40, 41] and often unlikely to hold. For exam-
343ple, smoking is more likely to be recorded in routine pri-
344mary care among smokers, and BMI is more likely to be
345recorded among overweight individuals. Therefore, sensi-
346tivity analysis is always advisable and there exist compre-
347hensive practical guides to approaching analysis with
348missing data [42, 43]. Even if observed, data on behav-
349iours such as smoking and alcohol consumption are un-
350likely to be recorded with perfect accuracy, particularly
351since they are often self-reported and are subject to social
352desirability bias [44].
353Unmeasured confounding EHRs rarely contain information
354on diet and physical activity, which may be important con-
355founders when looking at diabetes-related exposures and
356outcomes. Linkage to other sources may overcome this
357issue in some situations (e.g. some biobanks collect
358cross-sectional information on dietary intake). In some
359cases, the proxies may allow some degree of adjustment
360for unobserved variables. For example, statin use may be a
361reasonable proxy for high cholesterol where actual choles-
362terol values are not recorded. If such options are not avail-
363able, a negative control can be an informative way of in-
364vestigating the impact of unmeasured confounding [45].
365This involves examining an association that could plausi-
366bly be affected by the same unmeasured confounders as the
367primary association of interest, but where the true associa-
368tion is expected to be null. If the result obtained is close to
369the known association, this provides reassurance that un-
370measured confounding is unlikely to be substantially bias-
371ing the results of the primary analysis. Such a method has
372been successfully employed by Jackson et al in debates
373over influenza vaccinations [46]. The authors estimated a
374protective association between vaccine use and trauma
375hospitalisation, suggesting that unmeasured confounding
376may be responsible for the observed reduction in respira-
377tory hospitalisation.
378Recommendations
379Although the challenges discussed in this paper were not iden-
380tified systematically and were not intended to form an exhaus-
381tive list, they lead us to outline some key recommendations for
382best practice when studying diabetes using EHRs
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383 Although the challenges discussed in this paper were not
384 identified systematically and were not intended to form an
385 exhaustive list, they lead us to outline some key recommen-
386 dations for best practice when studying diabetes using EHRs.
387 Conclusions
388 EHRs offer great potential for the study of complex questions
389 beyond the scope of traditional clinical and observational
390 studies due to the breadth and timeliness of available data
391 and the ability for linkage to secondary care, mortality data
392 and disease registries. As such, there is a great opportunity to
393 allow for more accurate characterisation of diabetes type, pro-
394 gression of disease and quality of care.
395 The increasing quantity and quality of computerised
396 health-related data offers exciting opportunities for research
397 in diabetes. However, the danger of poor quality research with
398 misleading results is high and could result in deleterious ef-
399 fects on patient care and on prescribing. Improvements in
400 reporting of research, driven by initiatives such as the
401 Reporting of Studies Conducted using Observational
402 Routinely Collected Health Data (RECORD) reporting guide-
403 lines statement, may make it easier to identify the most rigor-
404 ous and reliable research [47]. Further, sharing of code lists
405 and statistical code may improve reproducibility of research
406 using EHRs. Alongside these improvements in transparent
407 reporting, increasing awareness of the methodological chal-
408 lenges, such as those outlined in this paper, is needed to help
409ensure that studies based on EHR data produce valid results
410that usefully add to the evidence base.
411
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              Key recommendations
1
To address any question in diabetes epidemiology, we must be able to confidently identify a 
population of individuals with diabetes within the EHR. Consider whether algorithms combining 
diagnostic, therapeutic and demographic information may improve ascertainment of diabetes 
status, type and duration compared with the use of coded diagnostic data alone
Where possible, include only incident users of medications when examining treatment effects 
and only compare treatments that would be used at similar stages of the disease. Beyond the 
estimation of treatment effects, it is still important to consider whether combining prevalent and 
incident cases of diabetes within a study is appropriate for the question of interest
At any given point in time, avoid using future information to either define inclusion into the study 
population or to define any variable for an individual
Be aware of the possibility of problematic time-dependent confounding if studying a time-varying 
exposure (be it a treatment or otherwise) and that advanced causal methods for handling such 
problems tend to make strong assumptions
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